Case Study: Augmenting Prostate Imaging Programs with OnQ™ Prostate

In this case study, Dr. Ross Schwartzberg of Imaging Healthcare Specialists shares how implementing OnQ™ Prostate transformed their prostate MRI program. Learn how Restriction Spectrum Imaging (RSI) technology improves lesion conspicuity, supports more accurate targeting, and strengthens collaboration across the care team.

Fill out the form below to read this case study:


More Resources

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation

07/29/2026

Read Your Segmentations in the Same Space You Read the Study: Native Space Outputs in NeuroQuant v5.3.0

Review lesion segmentations directly on your original MRI images with NeuroQuant® v5.3.0.

07/23/2026

What AAIC 2026 Told Us About the Future of Dementia Imaging — And Where NeuroQuant Fits

Quantitative MRI brain volumetry with NeuroQuant.

07/09/2026

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai’s health system network
Scroll to Top